Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson discuss new oral semaglutide and the SOUL trial which lowered death, MI and stroke rates by 14% in patients with diabetes. December 18, 2024 2024 | Cardiology | This Week in Obesity | Trial | Video Disclosures: TBD Article Navigation Dr. McGuire, Dr. Jastreboff and Dr. C Michael Gibson discuss the SURMOUNT 1 Trial of Tirzepatide and how we may be able to diminish the progression from pre-diabetes to diabetes. Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson discuss the SUMMIT trial and how GLP-1 agonists may be a new pillar in the treatment for HFpEF and obesity.
